Corneal Cross-Linking for Brittle Cornea Syndrome.
OBJECTIVE
To describe corneal cross-linking (CXL) as a treatment option for brittle cornea syndrome (BCS).


METHODS
Case report.


RESULTS
Ethical decision making enabled bilateral sequential transepithelial CXL in an 11-year-old girl with BCS. Postoperative courses were uneventful with a bilateral stromal demarcation line, unchanged corneal transparency, constant endothelial cell density, and stable topography 2 years after intervention.


CONCLUSIONS
Modified CXL can safely be performed in patients with BCS. Ethical review may be helpful for interventions deviating from standard practice.
*Department of Ophthalmology, Lucerne Cantonal Hospital, Lucerne, Switzerland; and †Ethics Committee for Research on Humans, Department of Health, Lucerne, Switzerland.
Claude
C
Kaufmann
Gregor
G
Schubiger
Michael A
MA
Thiel
D002648:Child; D003094:Collagen / Q000378:metabolism*; D003319:Corneal Stroma / Q000378:metabolism*; D003432:Cross-Linking Reagents; D004268:DNA-Binding Proteins / Q000235:genetics; D005124:Eye Abnormalities / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D005260:Female; D006801:Humans; D007593:Joint Instability / Q000151:congenital* / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D009154:Mutation; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D012256:Riboflavin / Q000627:therapeutic use*; D012868:Skin Abnormalities / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D014157:Transcription Factors / Q000235:genetics; D014466:Ultraviolet Rays; D014792:Visual Acuity
D003432:Cross-Linking Reagents; D004268:DNA-Binding Proteins; C487762:PRDM5 protein, human; D017319:Photosensitizing Agents; D014157:Transcription Factors; D003094:Collagen; D012256:Riboflavin